Evidence map›Paper›PMID 16328505›Full record

ReviewEuropean journal of nuclear medicine and molecular imaging2005

Human gene therapy and imaging in neurological diseases.

Andreas H Jacobs, Alexandra Winkler, Maria G Castro, Pedro Lowenstein

Erratum issuedOpen access · greenAbstract readReview
In one paragraph

Review in European journal of nuclear medicine and molecular imaging, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. The value of EGFRvIII as the target for glioma vaccines.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2014
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Andreas H JacobsMax Planck-Institute for Neurological Research, Center of Molecular Medicine (CMMC) and Department of Neurology, University of Cologne, Cologne, Germany. Andreas.Jacobs@pet.mpin-koeln.mpg.de
Alexandra Winkler
Maria G Castro
Pedro Lowenstein
Cedars-Sinai Medical Center · USMax Planck Institute for Metabolism Research · DEUniversity of California, Los Angeles · USUniversity of Cologne · DE

Funding

Gutless Adenovirus Mediated Gene Therapy for GliomaU01NS052465 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2007 to 2011
$3.1M
Engineering the Brain Immune System for Tumor TherapyR01NS057711 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2009 to 2013
$2.0M
Gene Therapy for Neurological DiseasesR01NS042893 · NINDS · CEDARS-SINAI MEDICAL CENTER · PI LOWENSTEIN, PEDRO R · 2002 to 2006
$1.8M
Brain immune responses:Cellular & Molecular MechanismsR01NS061107 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2008 to 2012
$1.7M
Gene Therapy and the Brain: Neuroimmune InteractionsR01NS054193 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2007 to 2011
$1.6M
Targeted Toxin for Brain Cancer Gene TherapyR21NS054143 · NINDS · CEDARS-SINAI MEDICAL CENTER · PI CASTRO, MARIA G · 2007 to 2008
$383k
NINDS NIH HHS R01 NS042893NINDS NIH HHS R01 NS054193NINDS NIH HHS R01 NS057711NINDS NIH HHS R01 NS061107NINDS NIH HHS R21 NS054143NINDS NIH HHS U01 NS052465
6 · The paper itself

Abstract

Molecular imaging aims to assess non-invasively disease-specific biological and molecular processes in animal models and humans in vivo. Apart from precise anatomical localisation and quantification, the most intriguing advantage of such imaging is the opportunity it provides to investigate the time course (dynamics) of disease-specific molecular events in the intact organism. Further, molecular imaging can be used to address basic scientific questions, e.g. transcriptional regulation, signal transduction or protein/protein interaction, and will be essential in developing treatment strategies based on gene therapy. Most importantly, molecular imaging is a key technology in translational research, helping to develop experimental protocols which may later be applied to human patients. Over the past 20 years, imaging based on positron emission tomography (PET) and magnetic resonance imaging (MRI) has been employed for the assessment and "phenotyping" of various neurological diseases, including cerebral ischaemia, neurodegeneration and brain gliomas. While in the past neuro-anatomical studies had to be performed post mortem, molecular imaging has ushered in the era of in vivo functional neuro-anatomy by allowing neuroscience to image structure, function, metabolism and molecular processes of the central nervous system in vivo in both health and disease. Recently, PET and MRI have been successfully utilised together in the non-invasive assessment of gene transfer and gene therapy in humans. To assess the efficiency of gene transfer, the same markers are being used in animals and humans, and have been applied for phenotyping human disease. Here, we review the imaging hallmarks of focal and disseminated neurological diseases, such as cerebral ischaemia, neurodegeneration and glioblastoma multiforme, as well as the attempts to translate gene therapy's experimental knowledge into clinical applications and the way in which this process is being promoted through the use of novel imaging approaches.

Indexed as

Gene Expression ProfilingGene TargetingGenetic TherapyHumansMagnetic Resonance ImagingMolecular Probe TechniquesNervous System DiseasesPositron-Emission Tomography

Identifiers

PMID16328505
PMCPMC2902257
OpenAlexW2001575816

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.